Autologous Stem Cell & Non-stem Cell Therapies Market

The global autologous stem cell & non-stem cell therapies market is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period. The major factors driving the growth of this market are the rising approvals for autologous CAR T cell therapies, increasing R&D investments for the development of autologous cell-based therapeutics, and a growing demand for personalized medicine.

The players operating in the autologous stem cell & non-stem cell therapies market are Gilead Sciences, Inc.  (US), Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), Iovance Biotherapeutics, Inc. (US), Johnson & Johnson (US), Vericel Corporation (US), JW (Cayman) Therapeutics Co. Ltd (China), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea), ), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea) and Anterogen.Co., Ltd. (South Korea).

To know about the assumptions considered for the study download the pdf brochure

GILEAD SCIENCES, INC.  (US)

Gilead Sciences, Inc. (US) held the leadership position in the autologous stem cell & non-stem cell therapies market in 2023. The company offers two FDA-approved autologous CAR T cell therapies namely YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma mantle cell lymphoma (MCL) and B-cell precursor acute lymphoblastic leukemia. The company operates in more than 35 countries in the European, North American, Asia Pacific, South American, African, and Middle Eastern regions. Gilead Sciences has nine manufacturing facilities spread across California, Ireland, Canada, and the Netherlands.

BRISTOL-MYERS SQUIBB COMPANY (US)

Bristol-Myers Squibb Company is a major player in the autologous stem cell & non-stem cell therapies market in 2023. The company operates under one segment that is focused on the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products. Pharmaceutical products offered by the company include biologics (chemically synthesized molecules produced from biological process) and chimeric antigen receptors (CAR-T) based cell therapies such as ABECMA (idecabtagene vicleucel) and BREYANZI (lisocabtagene maraleucel), which received FDA approvals in 2021 for the treatment of adult patients with relapsed or refractory multiple myeloma and adult patients with relapsed or refractory large B-cell lymphoma (LBCL) or relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) respectively.

The company has established manufacturing facilities in the U.S., Puerto Rico, Switzerland, Ireland, and the Netherlands and offers products in the North American, European, and Asia Pacific regions through its network of distributors, wholesalers, and specialty pharmacies.

NOVARTIS AG (SWITZERLAND)

Novartis AG is a healthcare company that focuses on discovering, developing, manufacturing, and marketing innovative as well as generic pharmaceuticals and biotechnology products. The company operates through one business segment called innovative medicines (patent-protected prescription medicines). Novartis offers autologous non-stem cell-based therapeutic products under its Innovative Medicines segment. The company’s product, Kymriah, an autologous CAR T-cell-based therapeutic drug for the treatment of young and adult patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL), is major contributors to the autologous stem cell & non-stem cell therapies market. The company also has a strong geographic presence with distribution channels across North America, Europe, Asia Pacific, Latin America, and Africa. The company also focuses on collaborating with other market players over the years, which supports its leading position in the autologous stem cell & non-stem cell therapies market.

Related Reports:

Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]